Rectosigmoid cancer forms in a unique location between the sigmoid colon and rectum, creating treatment challenges that differ from other colorectal cancers. The choice of therapy depends on where the tumor sits, how advanced it is, and careful evaluation by a medical team. Understanding your options can help you face this diagnosis with greater confidence.

When Cancer Sits at a Crossroads

The goal of treating rectosigmoid cancer is to remove or destroy cancerous cells, prevent the disease from spreading, and help patients maintain the best possible quality of life. Treatment plans are highly individualized, taking into account the exact location of the tumor, how deeply it has grown into the bowel wall, and whether it has reached nearby lymph nodes or other organs. Because rectosigmoid cancer sits at the junction between the sigmoid colon and rectum—typically 9 to 20 centimeters from the anal opening—doctors must carefully consider whether to treat it like rectal cancer or colon cancer.^[1]

The rectosigmoid region is particularly tricky because the rectum is tightly packed into the pelvis, surrounded by other organs and structures, making surgery more complex than in the colon. This anatomical challenge influences whether radiation therapy is needed before surgery.^[2] Medical teams use imaging tests to identify anatomical landmarks, such as the peritoneal reflection—a membrane that covers the upper rectum. Tumors below this landmark may benefit more from treatments given before surgery, while those above it may be managed differently.^[1]

Today’s standard treatments for rectosigmoid cancer have been refined over decades, and clinical trials are continuously exploring new therapies that may offer better outcomes with fewer side effects. The decision-making process involves a multidisciplinary team of surgeons, oncologists, radiologists, and other specialists who work together to design a treatment plan tailored to each patient’s unique situation.

The Foundation: Standard Treatment Approaches

Surgery remains the cornerstone of rectosigmoid cancer treatment. The primary goal is to remove the tumor along with a margin of healthy tissue and nearby lymph nodes to ensure no cancer cells are left behind. The type of surgery depends on the tumor’s size, location, and stage. For early-stage cancers confined to the inner lining of the bowel, surgeons may perform a local excision, removing only the tumor and a small amount of surrounding tissue. For more advanced cancers, a larger operation called a resection is necessary, removing a section of the bowel and then reconnecting the healthy ends.^[10]

When the tumor is located in the rectosigmoid region, surgeons must decide whether to treat it as a rectal or sigmoid cancer. This decision impacts whether the patient receives radiation therapy before surgery. Research shows that patients with tumors below the peritoneal reflection—a key anatomical landmark—may benefit significantly from receiving treatment before surgery rather than after.^[1] In one study, none of the 15 patients with tumors below this landmark who received pre-surgery treatment experienced cancer returning in the pelvis, compared to 25% of those who had surgery first.^[1]

Chemotherapy uses drugs to kill cancer cells throughout the body. The most commonly used drugs for rectosigmoid and colorectal cancers include fluorouracil (often called 5-FU), capecitabine, oxaliplatin, and irinotecan.^[13] Fluorouracil and capecitabine work by interfering with the cancer cells’ ability to make DNA, the genetic material they need to grow and divide. Capecitabine is an oral medication that the body converts into fluorouracil, making it more convenient for some patients.

Oxaliplatin and irinotecan are often added to fluorouracil-based chemotherapy for more advanced cancers or when there is a higher risk of the cancer spreading. Oxaliplatin damages cancer cell DNA in a different way, making it harder for cells to repair themselves. Irinotecan blocks an enzyme that cancer cells need to copy their DNA. These combinations are more powerful than single drugs alone, but they also bring more side effects.

Chemoradiotherapy combines chemotherapy with radiation therapy, typically used for rectal cancer. Radiation therapy uses high-energy beams to destroy cancer cells in a specific area. When given together, chemotherapy makes cancer cells more sensitive to radiation, improving the treatment’s effectiveness.^[13] This combination is often given before surgery to shrink the tumor, making it easier to remove completely and potentially allowing the surgeon to preserve important structures like the sphincter muscles that control bowel movements.^[10]

Clinical practice guidelines recommend that patients with locally advanced rectosigmoid cancer—meaning the tumor has grown through the bowel wall or reached nearby lymph nodes—should receive either chemotherapy alone or chemoradiotherapy before surgery. The choice depends on tumor location, imaging findings, and whether the surgeon believes they can completely remove the cancer.^[12] Studies show that patients who received pre-surgery therapy had tumors with higher T stages (indicating deeper growth into the bowel wall) and more positive or close margins on imaging, yet their outcomes were comparable to those who had surgery first.^[1]

After surgery, some patients receive additional chemotherapy called adjuvant therapy. This treatment aims to eliminate any microscopic cancer cells that might remain in the body, reducing the risk of the cancer coming back. The decision to give adjuvant chemotherapy depends on what the pathologist finds when examining the removed tissue under a microscope—particularly whether cancer cells have spread to lymph nodes and how deeply the tumor invaded the bowel wall.^[15]

Common Side Effects and What to Expect

Every cancer treatment comes with potential side effects, though not everyone experiences them the same way. Surgery for rectosigmoid cancer can lead to temporary changes in bowel habits. Some patients experience diarrhea or loose stools because part of the colon has been removed, affecting the body’s ability to absorb water from stool. Others may struggle with constipation. These changes often improve over time as the body adjusts, though some people need dietary modifications or medications to manage symptoms.^[19]

Chemotherapy side effects depend on which drugs are used. Fluorouracil and capecitabine commonly cause diarrhea, mouth sores, and a condition called hand-foot syndrome, where the palms and soles become red, swollen, and painful. Oxaliplatin is known for causing peripheral neuropathy—tingling, numbness, or pain in the hands and feet that can be triggered or worsened by cold temperatures. Irinotecan often causes diarrhea, which can be severe and requires prompt medical attention. Most patients also experience fatigue, nausea, and temporary decreases in blood cell counts, which can increase the risk of infections.^[13]

Radiation therapy to the pelvis can cause skin irritation in the treatment area, similar to a sunburn. Patients may also experience increased urinary frequency, bladder irritation, and diarrhea during treatment. These effects typically resolve within weeks after treatment ends, though some people have long-term changes such as bowel urgency or radiation proctitis—inflammation of the rectum that can cause bleeding or discomfort.^[13]

Innovative Approaches: Treatment in Clinical Trials

Clinical trials are research studies that test new ways to prevent, detect, or treat diseases. For rectosigmoid cancer, many trials are exploring therapies that might work better than current standard treatments or cause fewer side effects. While these treatments are still being studied and their benefits are not yet fully proven, they represent hope for improved outcomes in the future.

Targeted therapy is one promising area of research. Unlike chemotherapy, which affects all rapidly dividing cells in the body, targeted therapies are designed to attack specific molecules or pathways that cancer cells need to grow and survive. For colorectal cancers, several targeted drugs have been approved for advanced disease and are being studied for earlier-stage cancers.^[10] These drugs work by blocking signals that tell cancer cells to multiply or by cutting off the blood supply that tumors need to grow.

Immunotherapy is another exciting frontier. This type of treatment helps the patient’s own immune system recognize and destroy cancer cells. Some colorectal cancers have genetic changes that make them particularly responsive to immunotherapy. Researchers are conducting clinical trials to determine whether immunotherapy can benefit patients with rectosigmoid cancer, either alone or in combination with chemotherapy and radiation.^[10]

Clinical trials follow a structured process divided into phases. Phase I trials test a new treatment in a small group of people to evaluate its safety, determine a safe dosage range, and identify side effects. Phase II trials involve larger groups to assess whether the treatment is effective and to further evaluate its safety. Phase III trials compare the new treatment to the current standard of care in large groups of patients to determine which works better. Only after a treatment successfully completes all phases can it be considered for approval by regulatory agencies.

Patients considering participation in a clinical trial should discuss the potential benefits and risks with their medical team. Trials are conducted in many locations, including major cancer centers in the United States, Europe, and other regions. Eligibility criteria vary depending on the specific trial, but generally include factors such as cancer stage, previous treatments received, and overall health status.^[7]

Most Common Treatment Methods

• Surgery
  • Local excision for early-stage tumors confined to the inner lining of the bowel
  • Bowel resection to remove a section of the intestine along with the tumor and nearby lymph nodes
  • Surgery timing may be after pre-surgery treatments like chemotherapy or radiation to shrink the tumor
• Chemotherapy
  • Fluorouracil (5-FU) and capecitabine to interfere with cancer cell DNA production
  • Oxaliplatin to damage cancer cell DNA and prevent repair
  • Irinotecan to block enzymes needed for cancer cell DNA copying
  • May be given before surgery (neoadjuvant), after surgery (adjuvant), or for advanced disease
• Radiation Therapy
  • High-energy beams directed at the tumor to destroy cancer cells in a specific area
  • Often used for tumors located below the peritoneal reflection
  • Typically given before surgery to shrink the tumor and improve surgical outcomes
• Chemoradiotherapy
  • Combination of chemotherapy and radiation given together
  • Chemotherapy makes cancer cells more sensitive to radiation effects
  • Commonly used for locally advanced rectosigmoid cancers before surgery
• Targeted Therapy
  • Drugs that attack specific molecules or pathways cancer cells need to grow
  • Block signals that tell cancer cells to multiply
  • Cut off blood supply that tumors need to grow
• Immunotherapy
  • Helps the patient’s immune system recognize and destroy cancer cells
  • Particularly effective for cancers with certain genetic changes
  • Being studied in clinical trials for rectosigmoid cancer

Living with and Beyond Treatment

Completing treatment for rectosigmoid cancer marks an important milestone, but it also brings new considerations. Regular follow-up care is essential to monitor for any signs that the cancer has returned and to manage any long-term effects of treatment. Follow-up schedules vary depending on the original cancer stage and treatments received, but typically include physical examinations, blood tests to check tumor markers, and imaging studies at specific intervals.^[17]

Many survivors experience ongoing digestive changes. Bowel movements may become more frequent or urgent, and some people have difficulty controlling when they need to go. These challenges can improve with time, dietary adjustments, and sometimes medication. Working with a dietitian who specializes in oncology can help patients identify foods that ease symptoms and provide adequate nutrition.^[19]

Lifestyle choices play an important role in recovery and long-term health. Research suggests that survivors who maintain a healthy body weight, eat a diet rich in fruits, vegetables, and whole grains while limiting red and processed meats, exercise regularly, avoid smoking, and limit alcohol consumption may have better long-term outcomes.^[20] These same habits that may help reduce the risk of the cancer returning can also improve overall quality of life and reduce the risk of other health problems.

The emotional impact of cancer can persist long after physical treatment ends. Many survivors benefit from support groups where they can connect with others who have faced similar challenges. Some cancer centers offer survivorship programs that address not just physical health but also emotional well-being, financial concerns, and practical aspects of returning to work and daily activities.^[17]

Creating a survivorship care plan with your medical team can help you understand what to expect after treatment. This plan should outline your follow-up schedule, potential late effects of treatment to watch for, recommendations for healthy living, and guidelines for cancer screening. Staying engaged in your care and maintaining open communication with your healthcare providers helps ensure that any concerns are addressed promptly.^[19]